Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10966289 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2024.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VEGF in psoriatic arthritis: Systematic review and meta-analysis.
Clin Chim Acta
February 2025
Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Psoriatic arthritis (PsA), a chronic autoimmune disease of unclear aetiology, is associated with dysregulated angiogenesis due to the proliferation, migration, and differentiation of endothelial cells. Vascular endothelial growth factor (VEGF) plays a key role such that PsA patients exhibit skin and joint symptoms, e.g.
View Article and Find Full Text PDFCurrent Concepts and Medical Management for Patients with Radiographic Axial Spondyloarthritis.
Hip Pelvis
December 2024
Division of Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea.
Article Synopsis
- * Patients may experience a range of symptoms from mild joint stiffness to severe spinal fusion and can develop extraarticular issues like uveitis and inflammatory bowel disease.
- * Diagnosis has evolved with new criteria emphasizing early detection, and treatment typically starts with anti-inflammatory drugs and progresses to stronger medications like biologics and Janus kinase inhibitors as needed.
Advances in the management of psoriatic arthritis in adults.
BMJ
November 2024
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
Article Synopsis
- * Management starts with assessing the patient's skin and joints while screening for other health issues, followed by a mix of therapies like education, lifestyle changes, and physiotherapy.
- * Treatment options include non-steroidal anti-inflammatory drugs and disease-modifying therapies such as methotrexate and biologics, but there’s a need for better biomarkers to personalize these treatments for each patient.
A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report.
Front Immunol
July 2024
Department of Rheumatology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Article Synopsis
- Reactive arthritis (ReA) is a type of arthritis related to previous infections and features arthritis, skin symptoms like keratoderma blennorrhagicum, and other manifestations.
- A case study detailed in the article illustrates ReA following a urinary tract infection, initially treated with sulfasalazine and thalidomide, which helped with arthritis but not skin issues.
- Switching to tofacitinib showed significant improvement in the persistent skin rash after 20 days, highlighting its potential effectiveness in treating challenging cases of ReA with severe skin involvement.
Use of sulfasalazine for psoriasis: An evidence-based review.
JAAD Int
June 2024
Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!